+

US20060035899A1 - Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein - Google Patents

Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein Download PDF

Info

Publication number
US20060035899A1
US20060035899A1 US11/222,601 US22260105A US2006035899A1 US 20060035899 A1 US20060035899 A1 US 20060035899A1 US 22260105 A US22260105 A US 22260105A US 2006035899 A1 US2006035899 A1 US 2006035899A1
Authority
US
United States
Prior art keywords
lower alkyl
oxo
amino
pyrazine
thiopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/222,601
Inventor
Gregoire Prevost
Marie-Odile Lonchampt
Thomas Gordon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority to US11/222,601 priority Critical patent/US20060035899A1/en
Publication of US20060035899A1 publication Critical patent/US20060035899A1/en
Assigned to IPSEN PHARMA S.A.S. reassignment IPSEN PHARMA S.A.S. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SOCIETE DE CONSEILS DE RECHERCHES ET D`APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.)
Assigned to IPSEN PHARMA S.A.S. reassignment IPSEN PHARMA S.A.S. CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY NAME PREVIOUSLY RECORDED AT REEL: 022466 FRAME: 0793. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Assignors: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates in particular to the use of derivatives of cysteine for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein.
  • diseases include in particular diseases linked to the following biological functions or disorders: smell, taste, perception of light, neurotransmission, neurodegeneration, endocrine and exocrine gland functions, autocrine and paracrine regulation, arterial tension, embryogenesis, benign cell proliferation, oncogenesis, viral infection, immunological functions, diabetes, obesity, and benign and malign proliferative diseases.
  • the G proteins are in fact the structural association of three distinct sub-units called ⁇ , ⁇ , and ⁇ , but operate as dissociable entities constituted by ⁇ sub-units on the one hand and ⁇ / ⁇ dimers on the other hand.
  • the G proteins participate in the transmission of signals outside the cell thanks to its interaction with receptors with seven transmembrane domains inside using different effectors including adenylate cyclase, phospholipase C or also the ionic channels.
  • the adenylate cyclase enzyme generates cyclic AMP (cAMP) (cf. Gilman, A. G. Biosci. Rep. 15, 65-97 (1995)).
  • cAMP cyclic AMP
  • bacterial toxins such as Vibrio cholera and Bortella pertussis
  • peptides such as mastoparan and suramin
  • G proteins cf. Freissmuth, M., Boehm, S., Beindl, W., et al. Mol. Pharmacol. 49, 602-611 (1996); Boehm, S., Huck, S., Motejlek, A., et al. Journal of Neurochemistry 66, 1019-1026 (1996); Cachero, T. G., Rigual, R., Rocher, A. & Gonzalez, C. Eur. J. Neurosci.
  • the choleric toxin modifies the as sub-unit of the G protein by adding an ADP-ribose originating from the NAD to an arginine-specific acceptor site. This completely blocks the activity of the GTPase, provoking persistent stimulation of its next effector, adenylate cyclase and leading to overproduction of cAMP.
  • the harmful effects of an abnormal cAMP level are also known and occur in particular at the level of the following biological functions or disorders: smell, taste, perception of light, neurotransmission, neurodegeneration, endocrine and exocrine gland functions, autocrine and paracrine regulation, arterial tension, embryogenesis, benign cell proliferation, oncogenesis, viral infection and immunological functions, diabetes and obesity.
  • X represents R 12 and Y represents R 8 , or X and Y complete a ring with 6 members, the X-Y set representing the —CH(R 8 )—CH(R 9 )-radical;
  • R 1 represents H, a lower alkyl or alkylthio radical
  • R 2 and R 3 represent independently H or a lower alkyl radical
  • R 4 represents H 2 or O
  • R 5 represents H, or one of the lower alkyl, lower alkenyl, lower alkynyl, aryl, lower arylalkyl, heterocycle or lower alkyl heterocycle radicals, these radicals being optionally substituted by radicals chosen from the group comprising a lower alkyl radical, —O—R 10 , —S(O) m R 10 (m representing 0, 1, or 2), —N(R 10 )(R 11 ), —N—C(O)—R 10 , —NH—(SO 2 )—R 10 , —CO 2 —R 10 , C(O)—N(R 10 )(R 11 ), and —(SO 2 )—N(R 10 )(R 11 );
  • R 6 and R 7 represent independently H, a —C(O)—NH—CHR 13 —CO 2 R 14 radical, or one of the lower alkyl, aryl, lower arylalkyl, heterocycle or lower alkyl heterocycle radicals, these radicals being optionally substituted by radicals chosen from the group comprising the OH, alkyl or lower alkoxy, N(R 10 )(R 11 ), COOH, CON(R 10 )(R 11 ), and halo radicals,
  • R 6 and R 7 form together an aryl radical or a heterocycle
  • R 8 and R 9 represent independently, H, or one of the lower alkyl, aryl, lower arylalkyl, heterocycle or lower alkyl heterocycle radicals, these radicals being optionally substituted by radicals chosen from the group comprising the OH, alkyl or lower alkoxy, N(R 10 )(R 11 ), COOH, CON(R 10 )(R 11 ) and halo radicals,
  • R 8 and R 9 together form an aryl radical or a heterocycle
  • R 10 and R 11 represent independently H, an aryl radical or a heterocycle, or an alkyl, arylalkyl or lower alkyl heterocycle radical;
  • R 12 represents NR 9 , S, or O
  • R 13 represents a lower alkyl radical optionally substituted by a radical chosen from the lower alkyl, —OR 10 , S(O) m R 10 (m representing 0, 1, or 2) and —N(R 10 )(R 11 ) radicals;
  • R 14 represents H or a lower alkyl radical
  • W 1 represents a remainder originating from a cysteine in reduced or non reduced form
  • Ar represents a radical derived from an aminobenzoic acid, the aromatic ring of which is optionally substituted;
  • W 2 represents an amino acid, preferably an aliphatic amino acid; or also the compounds of general formula (C): in which:
  • Z 1 represents a lower alkyl radical
  • Z 2 and Z 3 both represent H or Z 2 and Z 3 together form a chain having 2 to 4 elements chosen from the —C(O)—, —CH 2 —, —CH(NH 2 )— and —S-radicals, it being understood that two successive elements are not both —C(O)—;
  • lower alkyl radical is understood a linear or branched alkyl radical containing 1 to 6 carbon atoms, and in particular the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl, pentyl, neopentyl, isopentyl, hexyl, isohexyl radicals.
  • heterocycle radical is understood a radical constituted by one or more rings and including at least one heteroatom.
  • arylalkyl, alkyl heterocycle, alkylthio or lower alkoxy radical is understood the radicals of which the alkyl radical has the meaning indicated previously.
  • the Ar radical included in formula (B) is optionally substituted by an alkyl radical comprising 1 to 6 carbon atoms or an aryl radical, these alkyl or aryl radicals themselves being optionally substituted preferentially by an alkoxy radical having 1 to 4 carbon atoms, fluoro, chloro, bromo.
  • the aryl radical preferably a phenyl can itself be substituted by an alkyl radical.
  • the compounds of general formula (B) are such that Ar represents a radical derived from an aminobenzoic acid the aromatic ring of which is substituted by a phenyl radical and W 2 represents an aliphatic amino acid.
  • the following compounds can be used to prepare medicaments intended to treat pathologies which result from the formation of the heterotrimeric G protein:
  • One of the following compounds is preferably used for the invention:
  • the invention therefore relates firstly to the use of the compounds of general formula (A), (B) or (C) as described previously for preparing a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein.
  • it relates to the use of said inhibitors for preparing medicaments intended to treat diseases linked to the following biological functions or disorders: smell, taste, perception of light, neurotransmission, neurodegeneration, endocrine and exocrine gland functions, autocrine and paracrine regulation, arterial tension, embryogenesis, viral infection, immunological functions, diabetes and obesity.
  • the invention relates to the use of compounds of general formula (A), (B) or (C) for preparing a medicament intended to treat cholera, Acquired Immune Deficiency Syndrome (AIDS), travel diarrhea and familial masculine precocious puberty.
  • a subject of the invention is also new products of general formula (A) numbered 1 to 7 and described hereafter in the examples, namely:
  • a subject of the invention is also said new products or their pharmaceutically acceptable salts as medicaments, as well as their use for preparing a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein.
  • it relates to the use of said products for preparing medicaments intended to treat diseases linked to the following biological functions or disorders: smell, taste, perception of light, neurotransmission, neurodegeneration, endocrine and exocrine gland functions, autocrine and paracrine regulation, arterial tension, embryogenesis, benign cell proliferation, oncogenesis, viral infection, immunological functions, diabetes, obesity, and benign and malign proliferative diseases.
  • the invention relates more particularly to the use of the compounds previously mentioned for preparing a medicament intended to treat cholera, Acquired Immune Deficiency Syndrome (AIDS), travel diarrhea and familial masculine precocious puberty.
  • AIDS Acquired Immune Deficiency Syndrome
  • compositions comprising a compound of the invention can be in the form of solids, for example powders, granules, tablets, gelatin capsules, liposomes or suppositories.
  • the appropriate solid supports can be, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine and wax.
  • compositions comprising a compound of the invention can also be presented in liquid form, for example, solutions, emulsions, suspensions or syrups.
  • suitable liquid supports can be, for example, water, organic solvents such as glycerol or glycols, as well as their mixtures, in varying proportions, in water.
  • the administration of a medicament according to the invention can be carried out by topical, oral, parenteral route, by injection (intramuscular, sub-cutaneous, intravenous, etc.), etc.
  • the administration route will of course depend on the type of disease to be treated.
  • the administration dose envisaged for a medicament according to the invention is comprised between 0.1 mg and 10 g depending on the type of pathology to be treated.
  • L-phenylalanine (10.0 g; 60.6 mmol) is combined with PtO2 (430 mg) in acetic acid (60 ml) and the mixture is hydrogenated overnight under 20-50 psi H 2 .
  • a 5% aqueous solution of HCl is added to the mixture in order to obtain a limpid solution and hydrogenation is continued until the consumption of hydrogen ceases.
  • the catalyst is eliminated by filtration and the filtrate is concentrated under reduced pressure.
  • the residue is taken up in methanol and water and the pH is adjusted to 4.4 by the addition of a 10% solution of NaOH.
  • the product obtained is recovered by filtration and used without further purification.
  • the keto-ester obtained is solubilized in xylenes (100 ml) and ammonium acetate (19.5 g; 0.25 mol) is added. The mixture is heated to reflux for approximately 3 hours with elimination of the excess AcONH 4 supernatant and of the water released by means of a Dean-Stark trap. The reaction mixture is concentrated under reduced pressure, taken up in AcOEt and washed with a saturated solution of NaHCO 3 (100 ml) and with a saturated solution of NaCl (100 ml). The AcOEt phase is dried over Na 2 SO 4 , filtered and concentrated under vacuum.
  • the crude product obtained is purified by flash chromatography on silica gel with a CHCl 3 /MeOH mixture 98/2 as eluant.
  • the fractions containing the pure product are combined and concentrated in order to produce the product (2.52 g; 40%) in the form of a slightly brown foam which is used in the following stage without additional purification.
  • the crude intermediate of Stage 1.c is solubilized in acetic acid (50 ml) containing a 10% Pd on carbon catalyst (152 mg), then hydrogenated under a pressure of 50 psi of H 2 for 18 hours at ambient temperature.
  • the catalyst is eliminated by filtration and the filtrate is heated at 70° C. for 2 hours.
  • the mixture obtained is concentrated under reduced pressure, dissolved in CH 2 Cl 2 (100 ml) and washed with a saturated solution of NaHCO 3 (100 ml).
  • the CH 2 Cl 2 layer is dried over Na 2 SO 4 , filtered and concentrated in order to produce a viscous oil which is used in the following stage without additional purification.
  • the intermediate of Stage 1.f (3.54 g; 4.69 mmol) is solubilized in trifluoroacetic acid (TFA, 80 ml) containing triisopropylsilane (1.92 ml; 9.38 mmol) and the reaction mixture is agitated at ambient temperature under nitrogen for one hour.
  • the reaction mixture is filtered and the filtrate is concentrated under reduced pressure.
  • the residue is extracted by trituration with an aqueous solution of TFA at 0.1% (6 ⁇ 65 ml) and filtered.
  • the crude product is purified by preparative HPLC on a C18 column using a gradient of 0 to 20% of CH 3 CN in an aqueous solution of TFA at 0.1% for 30 minutes.
  • the pure fractions of the product are collected and lyophilized.
  • the initial product is lyophilized twice from a dilute solution of HCl in order to produce the product in the form of its hydrochloride (740 mg; 32%).
  • Compound 2 is prepared according to diagram 1, Stages b to g, according to a method similar to that of Example 1, 2-bromoacetophenone replacing 2-bromo-2′-methylacetophenone in Stage b.
  • Compound 3 is prepared according to diagram 1, Stages b to g, according to a method similar to that of Example 1, Boc-(L)-Ser(Bzl)-OH replacing Cbz-(L)-cyclohexylalanine in Stage b and Stage d being replaced by a deprotection using TFA and iPr 3 SiH according to a method similar to reaction 1.g.
  • the product is obtained in the form of a pair of diastereoisomers in a proportion of 2:3.
  • Compound 4 is prepared according to diagram 1, Stages b to g, according to a method similar to that of Example 3, Boc-(L)-Thr(Bzl)-OH replacing Boc-(L)-Ser(Bzl)-OH in Stage b.
  • the keto-ester obtained is triturated with a 1:1 mixture of Et 2 O:hexanes (2 ⁇ 40 ml) then suspended in xylenes (100 ml).
  • Ammonium acetate (17.5 g; 0.23 mol) is added and the mixture is heated at reflux for approximately one hour and 30 minutes with elimination of the excess AcONH 4 and of the water released by means of a Dean-Stark trap.
  • the reaction medium is washed with a saturated solution of NaHCO 3 (50 ml), dried over Na 2 SO 4 , filtered and concentrated under vacuum in order to produce 6.66 g (98%) of desired product.
  • Intermediate 5.k is prepared according to a method similar to that of Stage 1.e, except for the fact that a molar proportion of 6/9 of BH 3 relative to the substrate is used.
  • diethylazodicarboxylate (166 ⁇ l; 1.05 mmol) is added dropwise over 10 minutes then the mixture is agitated again for 1 hour at ambient temperature.
  • the solvents are eliminated under reduced pressure and the crude product is purified by flash chromatography on silica gel with an AcOEt:hexanes mixture 3:2 as eluant.
  • the fractions containing the product are combined and concentrated under vacuum. After recrystallization from AcOEt and hexanes, the desired product is obtained in the form of a white solid (863 mg; 96%).
  • Product 5 is prepared starting from intermediate 5.n according to a method similar to that of Stage 1.g.
  • Stage 7.n is carried out according to a method similar to Stage 5.n.
  • the crude product is used without further purification in the following stage.
  • the stage 7.o is carried out according to a method similar to Stage 5.o.
  • the MCF-7 cell lines (human pleural cells, breast cancer) were acquired from the American Tissue Culture Collection (Rockville, Md., USA).
  • MCF-7 cells (2.10 4 cells/well) seeded in 24-well plates are cultured for 5 days in Dulbecco's modified Eagle medium (Gibco-Brl, Cergy-Pontoise, France) completed with 10% of foetal calf serum inactivated by heating (Gibco-Brl, Cergy-Pontoise, France), 50000 units/l of penicillin and 50 mg/l streptomycin (Gibco-Brl, Cergy-Pontoise, France), and 2 mM of glutamin (Gibco-Brl, Cergy-Pontoise, France).
  • Dulbecco's modified Eagle medium Gibco-Brl, Cergy-Pontoise, France
  • the culture medium is replaced after two washes with a medium without a serum completed or uncompleted with the specified agents for a time indicated in the different figures.
  • Agents activating the production of cyclic AMP are then added at 37° C.
  • the reaction is stopped after 30 minutes by suppressing the medium and rapidly adding 100 ⁇ l of a 0.1N solution of HCl. These extracts are frozen at ⁇ 80° C. until they are used.
  • the concentration of cAMP is measured using a commercial measurement kit (reference NEK033 from NEN, Les Ulis, France), following the manufacturer's instructions.
  • the radioactivity is determined by a Gamma counter (Gamma Master-1277, LKB, Turku, Finland).
  • the MCF-7 cells (3000 cells/well) are cultured in 96-well plates in 80 ⁇ l of Dulbecco's modified Eagle medium (Gibco-Brl, Cergy-Pontoise, France) completed with 10% of foetal calf serum inactivated by heating (Gibco-Brl, Cergy-Pontoise, France), 50000 units/l of penicillin and 50 mg/l streptomycin (Gibco-Brl, Cergy-Pontoise, France), and 2 mM of glutamin (Gibco-Brl, Cergy-Pontoise, France) were seeded on a 96-well plate on day 0.
  • Dulbecco's modified Eagle medium Gibco-Brl, Cergy-Pontoise, France
  • the cells were treated on day 1 for 96 hours with increasing concentrations of up to 50 ⁇ M of each of the compounds to be tested. After this period, quantification of cell proliferation is determined by a colorimetric test, based on the cleavage of the WST1 tetrazolum salt by the mitochondrial dehydrogenases in the viable cells, leading to the formation of formazan (Boehringer Mannheim, Meylan, France). These tests are carried out in duplicate with 8 determinations per concentration tested. For each compound to be tested, the values included in the linear part of the sigmoid were retained for linear regression analysis and used to estimate the inhibitory concentration (IC 50 ).
  • MCF7 cells (5.105 cells/well) are cultured in 6 wells in Dulbecco's modified Eagle medium (Gibco-Brl, Cergy-Pontoise, France) completed with 10% of foetal calf serum inactivated by heat (Gibco-Brl, Cergy-Pontoise, France), a mixture of antibiotics: 50000 units/l of penicillin and 50 mg/l of streptomycin (Gibco-Brl, Cergy-Pontoise, France) and 2 mM of glutamin (Gibco-Brl, Cergy-Pontoise, France).
  • the cells are incubated for 48 hours in medium containing no serum in order to return the cells to a state of rest.
  • the cells are then treated for 1 hour either with compound I or with PD98059 (Calbiochem, France Biochem, Meudon, France), a specific inhibitor of MAP kinase activation.
  • the cells are then stimulated (or not) for 5 minutes with 12.5 ng/ml of epidermal growth factor (EGF).
  • EGF epidermal growth factor
  • the reaction is stopped by two washes with PBS (Gibco-Brl, Cergy-Pontoise, France), at 4° C. containing neither calcium nor magnesium and by adding 150 ⁇ l of lysis buffer at 4° C.
  • composition of which is the following: 10 mM of tris, 150 mM of NaCl, 2 mM of EGTA, 2 mM of dithiothreitol, 1 mM of PMSF, 2 mM of orthovanadate, 10 ⁇ g/ml of leupeptin and 10 ⁇ g/ml of aprotinin.
  • Measurement of the proteins contained in the extracts is carried out by Bradford's method (Biorad reagents, Ivry-Sur-Seine, France). These extracts are frozen at ⁇ 80° C. until they are used.
  • the activity of the MAP kinase is measured using a commercial measurement kit (reference RPN 84, Amersham Life Science, Les Ujis, France) following the manufacturer's instructions.
  • the radioactivity is determined using a Packard scintillation counter (Tricarb 5000CA).
  • vasoactive intestinal peptide was acquired from Bachem (Voisins le Bretonneux, France).
  • the choleric toxin, forskolin, isoproterenol, prostaglandin E2 and PD 98059 were acquired from Calbiochem (France Biochem, Meudon, France).
  • the compounds of formulae (I), (II), (III), (IV), (V), (VI) and (VII) were supplied by Biomeasure Inc. (Milford, Mass., USA). All these compounds were used following their manufacturers' recommendations.
  • FIG. 1 shows that activation of the adenylate cyclase by the choleric toxin (200 ng/ml) or by forskolin (10 ⁇ M) leads to a very significant increase in the cyclic AMP level.
  • Pretreatment of the cells for 30 minutes with 30 ⁇ M of comound (I) does not modify the production of cyclic AMP induced by the direct activator of the adenylate cyclase, forskolin.
  • the production of cyclic AMP stimulated by the direct activator of the sub-unit, the choleric toxin is greatly inhibited by compound (I). This shows that the adenylate cyclase itself is not modified by compound (I) and that the latter prevents the formation of the heterotrimeric complex.
  • FIG. 2 shows that treatment with VIP of MCF-7 human breast cancer cells increases the intracellular quantity of cyclic AMP in a concentration-dependent manner.
  • a VIP concentration of 10 nM which offers a quasi-optimum production of cyclic AMP is used for the following tests. This concentration agrees with the data already published relating to the T47D human breast cancer cell line.
  • FIG. 3 shows that a 30-minute pretreatment of the MCF-7 cells resulting from the in vitro cultures with the compound of formula (I) is sufficient to inhibit the accumulation of cyclic AMP cyclic stimulated by VIP in a concentration-dependent manner. An almost complete inhibition was obtained at a concentration of 100 ⁇ M of the compound of formula (I).
  • FIG. 4 shows that a treatment for an hour with the compound of formula (I) is sufficient to modify the response to VIP. Treatments of a longer duration (8 hours and 24 hours) continue to inhibit the production of cyclic AMP but the main effect is obtained very rapidly.
  • Compound (I) is also capable of inhibiting the formation of cyclic AMP induced by other agents which stimulate the receptors with seven transmembrane domains.
  • the activity of the adenylate cyclase greatly increased by the prostaglandin E 2 is inhibited by a treatment for 30 minutes with compound (I). This suggests that treatment of the cells with compound (I) modifies the heterotrimeric form of the G proteins by disassociating the sub-unit of the ⁇ / ⁇ dimer.
  • Inhibition of stimulation by VIP is not restricted to compounds of a structure analogous to that of the compound of formula (I). As shown in Table I, compounds (II), (III), (IV), (V), (VI) and (VII) tested in the same model are also capable of reducing the quantity of cyclic AMP induced by VIP.
  • FIG. 6 shows that treatment of the cells for 1 hour with compound (I) doubles the basal activity of the MAP kinase. This suggests that by preventing the formation of the heterotrimeric complex, compound (I) releases the heterodimer—which itself remains linked to the membrane and activates the ras route.
  • FIG. 7 shows that after stimulation of the MAP kinase by the growth factor EGF for 5 minutes, the activity of the enzyme is increased by approximately 7 times.
  • Pretreatment of the cells for 1 hour either with compound (I) or with PD98059, a specific inhibitor of MAP kinase activation, halves the activity of the MAP kinase.
  • Table II in fact shows that compounds (I), (II), (III) and (IV) are capable of inhibiting the in vitro proliferation of MCF7 human tumour cells. TABLE I Compound Inhibition at 30 ⁇ M (I) 86% (II) 71% (III) 59% (IV) 52% (V) 68% (VI) 52% (VII) 65% Effects of Compounds I, II, III and IV Incubated for 30 Minutes on the Production of Cyclic AMP Stimulated by VIP in MCF7 Cells.
  • the results of the IC 50 are expressed in ⁇ M and represent the average of 2 experiments.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)

Abstract

The invention relates to the use of cysteine derivatives for preparing a medicament intended to treat diseases which result from the formation of the heterotrimeric G protein. These diseases include in particular diseases linked to the following biological functions or disorders: smell, taste, perception of the light, neurotransmission, neurodegeneration, endocrine and exocrine gland functions, autocrine and paracrine regulation, arterial tension, embryogenesis, benign cell proliferation, oncogenesis, viral infection, immunological functions, diabetes, obesity, and benign :and malign proliferative diseases. Said cysteine derivatives include in particular: bis-1,1′-[7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine disulphide (I), and bis-1,1′-7-(2-amino-1-oxo-3-thiopropyl-(2-(1-naphtyl)-8-(2-methylpropyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazin-7-yl) disulphide (II).

Description

  • The present invention relates in particular to the use of derivatives of cysteine for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein. These diseases include in particular diseases linked to the following biological functions or disorders: smell, taste, perception of light, neurotransmission, neurodegeneration, endocrine and exocrine gland functions, autocrine and paracrine regulation, arterial tension, embryogenesis, benign cell proliferation, oncogenesis, viral infection, immunological functions, diabetes, obesity, and benign and malign proliferative diseases.
  • The G proteins are in fact the structural association of three distinct sub-units called α, β, and γ, but operate as dissociable entities constituted by α sub-units on the one hand and β/γ dimers on the other hand.
  • The G proteins participate in the transmission of signals outside the cell thanks to its interaction with receptors with seven transmembrane domains inside using different effectors including adenylate cyclase, phospholipase C or also the ionic channels. The adenylate cyclase enzyme generates cyclic AMP (cAMP) (cf. Gilman, A. G. Biosci. Rep. 15, 65-97 (1995)). Thus, it is known that, in order to activate the adenylate cyclase, it is necessary for the G proteins to be transitionally in a heterotrimeric form, in which form the monomer constituted by an α sub-unit is associated with the dimer constituted by the β and γ sub-units. It is only in this situation that the signal outside the cell can activate the α sub-unit of a G protein, which can, after disassociation, modulate the adenylate cyclase and modulate the production of cAMP.
  • It is also known that the β/γ dimers can directly activate the effectors leading to the activation of kinases regulated by extracellular signals (ERKs) or MAP kinases. A direct link between the β/γ sub-units and the src or src like kinases has been demonstrated (cf. Gutkind, J. S. J. Biol. Chem. 273, 1839-1842 (1998)).
  • Moreover, bacterial toxins such as Vibrio cholera and Bortella pertussis, peptides such as mastoparan and suramin have been presented as directly modulating the activity of the G proteins (cf. Freissmuth, M., Boehm, S., Beindl, W., et al. Mol. Pharmacol. 49, 602-611 (1996); Boehm, S., Huck, S., Motejlek, A., et al. Journal of Neurochemistry 66, 1019-1026 (1996); Cachero, T. G., Rigual, R., Rocher, A. & Gonzalez, C. Eur. J. Neurosci. 8, 2320-2327 (1996); Danilenko, M., Worland, P., Carlson, B., Sausville, E. A. & Sharoni, Y. Biochem. Biophys. Res. Commun. 196, 1296-1302 (1993); Beindl, W., Mitterauer, T., Hohenegger, M., Ijzerman, A. P., Nanoff, C. & Freissmuth, M. Mol. Pharmacol. 50, 415-423 (1996)).
  • For example, the choleric toxin modifies the as sub-unit of the G protein by adding an ADP-ribose originating from the NAD to an arginine-specific acceptor site. This completely blocks the activity of the GTPase, provoking persistent stimulation of its next effector, adenylate cyclase and leading to overproduction of cAMP.
  • The harmful effects of an abnormal cAMP level are also known and occur in particular at the level of the following biological functions or disorders: smell, taste, perception of light, neurotransmission, neurodegeneration, endocrine and exocrine gland functions, autocrine and paracrine regulation, arterial tension, embryogenesis, benign cell proliferation, oncogenesis, viral infection and immunological functions, diabetes and obesity.
  • The Applicant has just discovered that certain derivatives of cysteine, namely the compounds of general formula (A)
    Figure US20060035899A1-20060216-C00001
    corresponding to sub-formulae (A1) or (A2):
    Figure US20060035899A1-20060216-C00002
    in which:
  • X represents R12 and Y represents R8, or X and Y complete a ring with 6 members, the X-Y set representing the —CH(R8)—CH(R9)-radical;
  • R1 represents H, a lower alkyl or alkylthio radical;
  • R2 and R3 represent independently H or a lower alkyl radical;
  • R4 represents H2 or O;
  • R5 represents H, or one of the lower alkyl, lower alkenyl, lower alkynyl, aryl, lower arylalkyl, heterocycle or lower alkyl heterocycle radicals, these radicals being optionally substituted by radicals chosen from the group comprising a lower alkyl radical, —O—R10, —S(O)mR10 (m representing 0, 1, or 2), —N(R10)(R11), —N—C(O)—R10, —NH—(SO2)—R10, —CO2—R10, C(O)—N(R10)(R11), and —(SO2)—N(R10)(R11);
  • R6 and R7 represent independently H, a —C(O)—NH—CHR13—CO2R14 radical, or one of the lower alkyl, aryl, lower arylalkyl, heterocycle or lower alkyl heterocycle radicals, these radicals being optionally substituted by radicals chosen from the group comprising the OH, alkyl or lower alkoxy, N(R10)(R11), COOH, CON(R10)(R11), and halo radicals,
  • or R6 and R7 form together an aryl radical or a heterocycle;
  • R8 and R9 represent independently, H, or one of the lower alkyl, aryl, lower arylalkyl, heterocycle or lower alkyl heterocycle radicals, these radicals being optionally substituted by radicals chosen from the group comprising the OH, alkyl or lower alkoxy, N(R10)(R11), COOH, CON(R10)(R11) and halo radicals,
  • or R8 and R9 together form an aryl radical or a heterocycle;
  • R10 and R11 represent independently H, an aryl radical or a heterocycle, or an alkyl, arylalkyl or lower alkyl heterocycle radical;
  • R12 represents NR9, S, or O;
  • R13 represents a lower alkyl radical optionally substituted by a radical chosen from the lower alkyl, —OR10, S(O)mR10 (m representing 0, 1, or 2) and —N(R10)(R11) radicals;
  • R14 represents H or a lower alkyl radical;
  • or the compounds of general formula (B):
    W1—Ar—W2   (B)
    in which:
  • W1 represents a remainder originating from a cysteine in reduced or non reduced form;
  • Ar represents a radical derived from an aminobenzoic acid, the aromatic ring of which is optionally substituted;
  • W2 represents an amino acid, preferably an aliphatic amino acid;
    or also the compounds of general formula (C):
    Figure US20060035899A1-20060216-C00003
    in which:
  • Z1 represents a lower alkyl radical;
  • Z2 and Z3 both represent H or Z2 and Z3 together form a chain having 2 to 4 elements chosen from the —C(O)—, —CH2—, —CH(NH2)— and —S-radicals, it being understood that two successive elements are not both —C(O)—;
  • it being understood that the compounds of general formula (C) can also be presented in the form of dimers, when the Z2 radical represents a hydrogen atom which can be eliminated by oxidization;
  • or also a pharmaceutically acceptable salt of a compound of general formula (A), (B) or (C);
  • can be used to prepare medicaments intended to treat pathologies which result from the formation of the heterotrimeric G protein.
  • By lower alkyl radical, is understood a linear or branched alkyl radical containing 1 to 6 carbon atoms, and in particular the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl, pentyl, neopentyl, isopentyl, hexyl, isohexyl radicals. By heterocycle radical is understood a radical constituted by one or more rings and including at least one heteroatom. By arylalkyl, alkyl heterocycle, alkylthio or lower alkoxy radical, is understood the radicals of which the alkyl radical has the meaning indicated previously.
  • Preferably, the Ar radical included in formula (B) is optionally substituted by an alkyl radical comprising 1 to 6 carbon atoms or an aryl radical, these alkyl or aryl radicals themselves being optionally substituted preferentially by an alkoxy radical having 1 to 4 carbon atoms, fluoro, chloro, bromo. The aryl radical preferably a phenyl can itself be substituted by an alkyl radical.
  • Preferably also, the compounds of general formula (B) are such that Ar represents a radical derived from an aminobenzoic acid the aromatic ring of which is substituted by a phenyl radical and W2 represents an aliphatic amino acid.
  • In particular, the following compounds can be used to prepare medicaments intended to treat pathologies which result from the formation of the heterotrimeric G protein:
    • 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methylphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
    • 7-(2-amino-1-oxo-3-thiopropyl)-8-butyl-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
    • 7-(2-amino-1-oxo-3-thiopropyl)-8-(1-methylpropyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
    • 1-[2(R)-amino-3-mercaptopropyl]-2(S)-n-butyl-4-(1-naphthoyl)piperazine;
    • bis-1,1′-[7-(2-amino-1-oxo-3-thiopropyl)-2-(methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine]disulphide;
    • bis-1,1′-[7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine disulphide;
    • bis-1,1′-7-(2-amino-1-oxo-3-thiopropyl-(2-(1-naphthyl)-8-(2-methylpropyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazin-7-yl) disulphide;
    • the compound of formula:
      Figure US20060035899A1-20060216-C00004
    • the compound of formula:
      Figure US20060035899A1-20060216-C00005
    • 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
    • 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(phenylmethoxy)methyl-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
    • 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(1-phenylmethoxy)ethyl-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
    • 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(phenoxyethyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
    • 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methyoxyphenyl)-8-(phenoxyethyl)-5,6,7,8-tetrahydro-imidazo[1.2a]pyrazine, or its dimeric form;
    • and 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(phenylsulphonylethyl)-5,6,7,8-tetrahydro-imidazo[1.2a]pyrazine;
      or also a pharmaceutically acceptable salt of one of these compounds.
  • One of the following compounds is preferably used for the invention:
    • bis-1,1′-[7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine disulphide (I);
    • bis-1,1′-7-(2-amino-1-oxo-3-thiopropyl-(2-(1-naphthyl)-8-(2-methylpropyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazin-7-yl) disulphide (II);
    • 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methylphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine (III);
    • the compound of formula:
      Figure US20060035899A1-20060216-C00006
    • 7-(2-amino-1-oxo-3-thiopropyl)-8-butyl-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine (V);
    • bis-1,1′-[7-(2-amino-1-oxo-3-thiopropyl)-2-(methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine] disulphide (VI);
    • the compound of formula:
      Figure US20060035899A1-20060216-C00007
    • 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
    • 7-(2-amino-1-oxo-3-thiopropyl)-8-(1-methylpropyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
    • 1-[2(R)-amino-3-mercaptopropyl]-2(S)-n-butyl-4-(1-naphthoyl)piperazine.
      or a pharmaceutically acceptable salt of one of the latter.
  • More preferentially, one of the following compounds is used for the invention:
    • bis-1,1′-[7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine disulphide (I);
    • bis-1,1′-7-(2-amino-1-oxo-3-thiopropyl-(2-(1-naphthyl)-8-(2-methylpropyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazin-7-yl) disulphide (II);
    • 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methylphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine (III);
    • 7-(2-amino-1-oxo-3-thiopropyl)-8-butyl-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo(1.2a]pyrazine (V);
    • the compound of formula:
      Figure US20060035899A1-20060216-C00008
      or a pharmaceutically acceptable salt of one of the latter.
  • Finally, the following compounds are more particularly preferred:
    • bis-1,1′-[7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine disulphide (I);
    • bis-1,1′-7-(2-amino-1-oxo-3-thiopropyl-(2-(1-naphthyl)-8-(2-methylpropyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazin-7-yl) disulphide (II);
      or a pharmaceutically acceptable salt of one of the latter.
  • The invention therefore relates firstly to the use of the compounds of general formula (A), (B) or (C) as described previously for preparing a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein. In particular, it relates to the use of said inhibitors for preparing medicaments intended to treat diseases linked to the following biological functions or disorders: smell, taste, perception of light, neurotransmission, neurodegeneration, endocrine and exocrine gland functions, autocrine and paracrine regulation, arterial tension, embryogenesis, viral infection, immunological functions, diabetes and obesity.
  • More particularly, the invention relates to the use of compounds of general formula (A), (B) or (C) for preparing a medicament intended to treat cholera, Acquired Immune Deficiency Syndrome (AIDS), travel diarrhea and familial masculine precocious puberty.
  • A subject of the invention is also new products of general formula (A) numbered 1 to 7 and described hereafter in the examples, namely:
    • 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methylphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
    • 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
    • 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(phenylmethoxy)methyl-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
    • 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(1-phenylmethoxy)ethyl-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
    • 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(phenoxyethyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
    • 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methyoxyphenyl)-8-(phenoxyethyl)-5,6,7,8-tetrahydro-imidazo[1.2a]pyrazine, or its dimeric form;
    • and 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(phenylsulphonylethyl)-5,6,7,8-tetrahydro-imidazo[1.2a]pyrazine.
  • A subject of the invention is also said new products or their pharmaceutically acceptable salts as medicaments, as well as their use for preparing a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein. In particular, it relates to the use of said products for preparing medicaments intended to treat diseases linked to the following biological functions or disorders: smell, taste, perception of light, neurotransmission, neurodegeneration, endocrine and exocrine gland functions, autocrine and paracrine regulation, arterial tension, embryogenesis, benign cell proliferation, oncogenesis, viral infection, immunological functions, diabetes, obesity, and benign and malign proliferative diseases.
  • The products particularly preferred for use according to the invention are therefore the following:
    • bis-1,1′-[7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine disulphide;
    • bis-1,1′-7-(2-amino-1-oxo-3-thiopropyl-(2-(1-naphthyl)-8-(2-methylpropyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazin-7-yl) disulphide;
    • the compound of formula:
      Figure US20060035899A1-20060216-C00009
    • 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methylphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
    • 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
    • 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(phenylmethoxy)methyl-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
    • 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(1-phenylmethoxy)ethyl-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
    • 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(phenoxyethyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
    • 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methyoxyphenyl)-8-(phenoxyethyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine, or its dimeric form;
    • and 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(phenylsulphonylethyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
      or a pharmaceutically acceptable salt of one of the latter.
  • Similarly, the invention relates more particularly to the use of the compounds previously mentioned for preparing a medicament intended to treat cholera, Acquired Immune Deficiency Syndrome (AIDS), travel diarrhea and familial masculine precocious puberty.
  • The compounds of general formula (A) and their preparation are described in the Patent Application WO 97/30053 or in the examples hereafter. The compounds of general formula (B) and their preparation are described in the Patent Application WO 96/21456. Finally, the preparation of the compounds of general formula (C) is described in the Patent Application PCT WO 95/00497, except for the compound of formula (VII) for which the synthesis is described in the experimental part of this Application.
  • The pharmaceutical compositions comprising a compound of the invention can be in the form of solids, for example powders, granules, tablets, gelatin capsules, liposomes or suppositories. The appropriate solid supports can be, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine and wax.
  • The pharmaceutical compositions comprising a compound of the invention can also be presented in liquid form, for example, solutions, emulsions, suspensions or syrups. The appropriate liquid supports can be, for example, water, organic solvents such as glycerol or glycols, as well as their mixtures, in varying proportions, in water.
  • The administration of a medicament according to the invention can be carried out by topical, oral, parenteral route, by injection (intramuscular, sub-cutaneous, intravenous, etc.), etc. The administration route will of course depend on the type of disease to be treated.
  • The administration dose envisaged for a medicament according to the invention is comprised between 0.1 mg and 10 g depending on the type of pathology to be treated.
  • Unless they are defined in another manner, all the technical and scientific terms used here have the same meaning as that usually understood by an ordinary specialist in the field to which this invention belongs. Similarly, all the publications, patent applications, all the patents and all other references mentioned here are incorporated by way of reference.
    • EXAMPLES Example 1 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methylphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine: 1
  • Compound 1 was prepared according to the synthesis diagram below:
    Figure US20060035899A1-20060216-C00010
    • 1.a) Carbobenzyloxy-L-cyclohexylalanine
  • L-phenylalanine (10.0 g; 60.6 mmol) is combined with PtO2 (430 mg) in acetic acid (60 ml) and the mixture is hydrogenated overnight under 20-50 psi H2. A 5% aqueous solution of HCl is added to the mixture in order to obtain a limpid solution and hydrogenation is continued until the consumption of hydrogen ceases. The catalyst is eliminated by filtration and the filtrate is concentrated under reduced pressure. The residue is taken up in methanol and water and the pH is adjusted to 4.4 by the addition of a 10% solution of NaOH. The product obtained is recovered by filtration and used without further purification.
  • L-cyclohexylalanine (60.6 mmol) is suspended in water (100 ml), K2CO3 (8.36 g; 60.6 mmol) is added, then a solution of N-(benzyloxycarbonyloxy)succinimide (15.1 g; 60.6 mmol) in CH3CN (150 ml) and the mixture obtained is agitated vigorously for 45 minutes. The mixture is concentrated in order to produce a volume of approximately 100 ml and washed with Et2O (100 ml), then acidified with concentrated HCl and extracted with AcOEt (2×50 ml). The combined AcOEt phases are dried over Na2SO4, filtered and concentrated in order to produce a clear oil (17.27 g; 93%). NMR 1H (DMSO-d6): 7.5-7.6 (1H, d); 7.2-7.5 (5H, m); 5.0-5.1 (2H, s); 3.9-4.1 (1H, m); 0.7-1.8 (13H, m).
    • 1.b) 2-(1-(S)-((phenylmethoxy)carbonyl)-amino-2-(cyclohexyl)methyl)-4-(2-methylphenyl)-imidazole
  • Cbz-(L)-cyclohexylalanine (4.58 g; 15.0 mmol) and Cs2CO3 (2.44 g; 7.50 mmol) are placed in a 2:1 mixture of DMF:H2O (75 ml). The mixture obtained is agitated until it becomes homogeneous. The solvents are eliminated under reduced pressure, the residue is dissolved in DMF (60 ml) and 2-bromo-2′-methylacetophenone (3.20 g; 15.0 mmol) in DMF (30 ml) is added. The mixture is agitated overnight at ambient temperature then filtered and concentrated under reduced pressure. The keto-ester obtained is solubilized in xylenes (100 ml) and ammonium acetate (19.5 g; 0.25 mol) is added. The mixture is heated to reflux for approximately 3 hours with elimination of the excess AcONH4 supernatant and of the water released by means of a Dean-Stark trap. The reaction mixture is concentrated under reduced pressure, taken up in AcOEt and washed with a saturated solution of NaHCO3 (100 ml) and with a saturated solution of NaCl (100 ml). The AcOEt phase is dried over Na2SO4, filtered and concentrated under vacuum. The crude product obtained is purified by flash chromatography on silica gel with a CHCl3/MeOH mixture 98/2 as eluant. The fractions containing the pure product are combined and concentrated in order to produce the product (2.52 g; 40%) in the form of a slightly brown foam which is used in the following stage without additional purification.
    • 1.c) 2-(1-(S)-((phenylmethoxy)carbonyl)-amino-2-(cyclohexyl)methyl)-1-((2-ethoxy-2-oxo)ethyl)-4-(2-methylphenyl)-imidazole
  • Intermediate 1.b (2.52 g; 6.0 mmol) is solubilized in DMF (20 ml) and treated with K2CO3 (1.67 g, 12.1 mmol) and ethyl bromoacetate (1.34 ml; 12.5 mmol) is added. The mixture obtained is heated at 45° C. for one and a half hours. The mixture is diluted with ether (50 ml) and washed with a saturated solution of NaHCO3 solution (50 ml) then with a saturated solution of NaCl (50 ml). The ethereal layer is dried over Na2SO4, filtered and concentrated in order to produce an oil which is used in the following stage without additional purification.
  • Mass spectrum: 504.3 MH+.
    • 1.d) 8-(cyclohexylmethyl)-6-oxo-2-(2-methylphenyl)-imidazo[1,2-a]pyrazine
  • The crude intermediate of Stage 1.c is solubilized in acetic acid (50 ml) containing a 10% Pd on carbon catalyst (152 mg), then hydrogenated under a pressure of 50 psi of H2 for 18 hours at ambient temperature. The catalyst is eliminated by filtration and the filtrate is heated at 70° C. for 2 hours. The mixture obtained is concentrated under reduced pressure, dissolved in CH2Cl2 (100 ml) and washed with a saturated solution of NaHCO3 (100 ml). The CH2Cl2 layer is dried over Na2SO4, filtered and concentrated in order to produce a viscous oil which is used in the following stage without additional purification.
  • Mass spectrum: 324.3 MH+.
    • 1.e) 8-(cyclohexylmethyl)-2-(2-methylphenyl)-4,5,6,7-tetrahydro-imidazo[1,2-a]pyrazine
  • The crude intermediate of Stage 1.c is solubilized in THF (25 ml) and treated at ambient temperature with a 1M solution of BH3 in THF (25 ml) for half an hour then taken to reflux for 1 hour. The mixture is cooled down using an ice bath and 4N HCl (40 ml) is added dropwise at 0° C. The mixture is taken to ambient temperature then taken to reflux for 1 hour. The reaction medium is then cooled down, filtered and concentrated under reduced pressure. The residue is treated with a saturated solution of NaHCO3 (50 ml) and extracted with CH2Cl2 (3×50 ml). The CH2Cl2 phases are dried over Na2SO4, filtered and concentrated in order to produce a slightly brown oil (1.63 g; yield of 87% relative to Stages 1.c, 1.d and 1.e).
  • Mass-spectrum: 310.3 MH+.
    • 1f.) 8-(cyclohexylmethyl)-7-[2-(((1,1-dimethylethoxy)carbonyl)amino)-1-oxo-3-((triphenylmethyl)thio)propyl]-2-(2-methylphenyl)-4,5,6,7-tetrahydro-imidazo-[1.2a]-piperazine
  • Diisopropylcarbodiimide (908 μl; 5.80 mmol) and BocCys(trt)-OH (5.37 g; 11.6 mmol) are solubilized in CH2Cl2 (25 ml), the mixture obtained being agitated for 45 minutes. 8-(cyclohexylmethyl)-2-(2-methylphenyl)-4,5,6,7-tetrahydro-imidazo[1,2-a]pyrazine (1.63 g; 5.27 mmol) is then added. The reaction mixture is agitated overnight at ambient temperature. The solvent is eliminated under reduced pressure and the product obtained is purified by flash chromatography on silica gel with a CH2Cl2/MeOH mixture 98/2 as eluant. The pure fractions are concentrated in order to produce a viscous oil which is which is used in the following stage without additional purification.
  • Mass spectrum: 755.6 MH+.
    • 1.g) 7-(2-amino-1-oxo-3-(mercaptopropyl))-8-(cyclohexylmethyl)-2-(2-methylphenyl)-4,5,6,7-tetrahydro-imidazo-[1.2a]-piperazine: 1
  • The intermediate of Stage 1.f (3.54 g; 4.69 mmol) is solubilized in trifluoroacetic acid (TFA, 80 ml) containing triisopropylsilane (1.92 ml; 9.38 mmol) and the reaction mixture is agitated at ambient temperature under nitrogen for one hour. The reaction mixture is filtered and the filtrate is concentrated under reduced pressure. The residue is extracted by trituration with an aqueous solution of TFA at 0.1% (6×65 ml) and filtered. The crude product is purified by preparative HPLC on a C18 column using a gradient of 0 to 20% of CH3CN in an aqueous solution of TFA at 0.1% for 30 minutes. The pure fractions of the product are collected and lyophilized. The initial product is lyophilized twice from a dilute solution of HCl in order to produce the product in the form of its hydrochloride (740 mg; 32%).
  • Mass spectrum: 413.2 MH+. NMR 1H (DMSO-d6): 8.5-9.0 (3H, d, broad); 7.8-8.0 (1H, s); 7.5-7.7 (1H, d); 7.2-7.5 (3H, m); 5.8-6.1 (1H, m); 4.65-4.8 (1H, s); 4.5-4.7 (1H, d); 4.1-4.4 (2H, m); 3.8-4.0 (1H, m); 3.2-3.7 (H2O); 2.8-3.1 (2H, m); 2.35-2.5 (3H, s); 2.0-2.2 (1H, m); 1.8-2.05 (2H, m); 1.25-1.4 (4H, broad s); 1.3-0.9 (6H, m).
    • Example 2 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine: 2
  • Compound 2 is prepared according to diagram 1, Stages b to g, according to a method similar to that of Example 1, 2-bromoacetophenone replacing 2-bromo-2′-methylacetophenone in Stage b.
  • Mass spectrum: 399.2 MH+. NMR 1H (DMSO-d6): 8.5-8.9 (3H, broad d); 8.0-8.2 (1H, s); 7.8-8.0 (2H, d); 7.45-7.56 (2H, t); 7.35-7.5 (1H, t); 5.9-6.05 (1H, broad s); 4.65-4.8 (1H, s); 4.5-4.65 (1H, d); 4.1-4.35 (2H, m); 3.8-4.0 (1H, m); 3.2-3.8 (H2O); 3.25-3.4 (1H, t); 2.8-3.05 (2H, m); 2.05-2.2 (1H, d); 1.85-2.05 (2H, t); 1.55-1.75 (4H, broad s); 1.15-1.3 (1H, broad s); 1.2-0.9 (5H, m).
    • Example 3 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(phenylmethoxy)methyl-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine: 3
  • Compound 3 is prepared according to diagram 1, Stages b to g, according to a method similar to that of Example 1, Boc-(L)-Ser(Bzl)-OH replacing Cbz-(L)-cyclohexylalanine in Stage b and Stage d being replaced by a deprotection using TFA and iPr3SiH according to a method similar to reaction 1.g. The product is obtained in the form of a pair of diastereoisomers in a proportion of 2:3.
  • Mass spectrum: 453.2 MH+.
  • The retention times for the diastereoisomers are 6.58 and 7.07 minutes respectively in the following HPLC system:
    Eluant: 30-50% CH3CN/0.1% TFA
    Duration of elution: 24 minutes
    Detection: 254 nm
    Column: Vydac protein and C18 peptide
    • Example 4 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(1-phenylmethoxy)ethyl-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine: 4
  • Compound 4 is prepared according to diagram 1, Stages b to g, according to a method similar to that of Example 3, Boc-(L)-Thr(Bzl)-OH replacing Boc-(L)-Ser(Bzl)-OH in Stage b.
  • Mass spectrum: 467.3 MH+. NMR 1H (DMSO-d6): 8.5-8.9 (3H, d, broad); 8.0-8.1 (1H, s); 7.95-8.1 (2H, d); 7.4-7.5 (1H, t); 7.15-7.3 (1H, d); 7.0-7.2 (3H, m); 6.9-7.05 (2H, m); 5.85-5.95 (1H, d); 4.75-4.85 (1H, broad s); 4.65-4.8 (1H, broad s); 4.35-4.65 (3H, m); 4.1-4.25 (2H, q); 3.9-4.0 (3H, s); 2.8-3.1 (2H, m); 1.2-1.4 (3H, d).
    • Example 5 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-phenoxyethyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine: 5
  • Compound 5 was prepared according to the following synthesis diagram:
    Figure US20060035899A1-20060216-C00011
    Figure US20060035899A1-20060216-C00012
    • 5.b) 2-(1-(S)-((phenylmethoxy)carbonyl)-amino-2-(2-oxo-2-(phenylmethoxy)ethyl)-4-(2-methoxyphenyl)-imidazole
  • Cbz-(L)-Asp(Obzl)-OH (5.00 g; 14.0 mmol) and Cs2CO3 (2.28 g; 7.00 mmol) are mixed in a 1:1 mixture of DMF:H2O (75 ml). The mixture obtained is agitated until it becomes homogenous. The solvents are eliminated under reduced pressure, the residue is dissolved in DMF (60 ml) and 2-bromo-2′-methoxyacetophenone (3.21 g; 14.0 mmol) in DMF (30 ml) is added. The mixture obtained is agitated for half an hour at ambient temperature then filtered and concentrated under reduced pressure. The keto-ester obtained is triturated with a 1:1 mixture of Et2O:hexanes (2×40 ml) then suspended in xylenes (100 ml). Ammonium acetate (17.5 g; 0.23 mol) is added and the mixture is heated at reflux for approximately one hour and 30 minutes with elimination of the excess AcONH4 and of the water released by means of a Dean-Stark trap. The reaction medium is washed with a saturated solution of NaHCO3 (50 ml), dried over Na2SO4, filtered and concentrated under vacuum in order to produce 6.66 g (98%) of desired product.
  • Mass spectrum: 486.3 (MH+).
    • 5.i) 2-(1-(S)-((phenylmethoxy)carbonyl)-amino-2-((2-phenylmethoxy-2-oxo)ethyl)-1-((2-ethoxy-2-oxo)ethyl)-4-(2-methoxyphenyl)-imidazole
  • Intermediate 5.i is prepared according to a method similar to that of Stage 1.c.
  • Mass spectrum: 572.3 MH+.
    • 5.j) (6-oxo-2-(2-methoxyphenyl)-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazin-8-yl)-acetic acid
  • Intermediate 5.j is prepared according to a method similar to that of Stage 1.d.
  • Mass spectrum: 302.2 MH+. NMR 1H (DMSO-d6): 8.35-8.5 (1H, d, broad); 8.0-8.1 (1H, dd); 7.45-7.55 (1H, s); 7.15-7.25 (1H, m); 7.0-7.1 (1H, m); 6.9-7.0 (1H, m); 4.85-5.0 (1H, broad s); 4.55-4.75 (2H, q); 3.85-3.95 (3H, s); 2.8-2.95 (2H, d).
    • 5.k) 8-hydroxyethyl-2-(2-methoxyphenyl)-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazine
  • Intermediate 5.k is prepared according to a method similar to that of Stage 1.e, except for the fact that a molar proportion of 6/9 of BH3 relative to the substrate is used.
  • Mass spectrum: 274.3 MH+.
    • 5.l) 7-((1,1-dimethylethoxy)carbonyl)-8-hydroxyethyl-2-(2-methyoxyphenyl)-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazine
  • Intermediate 5.k (1.36 g; 5.0 mmol) is suspended in H2O (5 ml) and a mixture of di-t-butyldicarbonate (1.20 g; 5.5 mmol) in p-dioxane (10 ml) is added. The reaction medium is agitated vigorously and maintained at pH 8.0-8.4 by the dropwise addition of a 2.5N solution of NaOH until the reaction finishes (monitoring of the reaction by TLC on silica gel, eluant AcOEt:hexanes 3:2). The crude product is purified by flash chromatography on silica gel with an AcOEt:hexanes mixture 3:2 as eluant (Biotage system, pre-filled columns 4×15 cm). The fractions containing the product are combined and concentrated under vacuum in order to produce a white foam (1.60 g; 86%).
  • Mass spectrum: 374.3 MH+. NMR 1H (DMSO-d6): 7.95-8.05 (1H, d,d); 7.45-7.55 (1H, s); 7.10-7.25 (1H, m); 7.0-7.1 (1H, m); 6.9-7.05 (1H, m); 5.05-5.15 (1H, t); 4.25-4.35 (1H, t); 4.05-4.2 (1H, broad s); 4.0-4.1 (1H m); 3.9-4.0 (3H, s); 3.9-4.0 (1H, m); 3.25-3.35 (2H, m); 1.9-2.1 (2H, m); 1.15-1.25 (9H, s).
    • 5.m) 7-((1,1-dimethylethoxy)carbonyl)-8-phenoxyethyl-2-(2-methoxyphenyl)-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazine
  • Intermediate 5.1 (746 mg; 2.00 mmol) is dissolved in THF (10 ml) containing triphenylphosphine (550 mg; 2.1 mmol) and phenol (198 mg; 2.1 mmol). The mixture is cooled down to 0° C. under nitrogen and diethylazodicarboxylate (330 μl; 2.1 mmol) is added dropwise over 10 minutes. The reaction mixture is then agitated for 2 hours at ambient temperature. The reaction medium is then cooled down again to 0° C. and triphenylphosphine (275 mg; 1.05 mmol) and phenol (99 mg; 1.05 mmol) are added. Then diethylazodicarboxylate (166 μl; 1.05 mmol) is added dropwise over 10 minutes then the mixture is agitated again for 1 hour at ambient temperature. The solvents are eliminated under reduced pressure and the crude product is purified by flash chromatography on silica gel with an AcOEt:hexanes mixture 3:2 as eluant. The fractions containing the product are combined and concentrated under vacuum. After recrystallization from AcOEt and hexanes, the desired product is obtained in the form of a white solid (863 mg; 96%).
  • Mass spectrum: 450.4 MH+.
    • 5.n) 7-(2-(((1,1-dimethylethoxy)carbonyl)amino)-1-oxo-3-((triphenylmethyl) thio)propyl)-2-(2-methoxyphenyl)-8-(phenoxyethyl)-4,5,6,7-tetrahydro-imidazo-[1.2a]-piperazine
  • Intermediate 5.m (850 mg; 1.89 mmol) is treated with a mixture of TFA (10 ml) containing iPr3SiH (387 μl, 1.89 mmol) at ambient temperature for 20 min. The solvents are eliminated under reduced pressure and the crude product is divided between AcOEt (15 ml) and a saturated solution of NaHCO3 (15 ml). The AcOEt phase is dried over Na2SO4, filtered and concentrated under reduced pressure. The deprotected product is coupled to Boc-(L)-Cys(Trt)-OH according to a method similar to that of Stage 1.f (1.26 g; 84%).
    • 5.o) 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(phenoxyethyl)-4,5,6,7-tetrahydro-imidazo-[1.2a]-piperazine
  • Product 5 is prepared starting from intermediate 5.n according to a method similar to that of Stage 1.g.
  • Mass spectrum: 274.3 MH+. NMR 1H (DMSO-d6 at 90° C.): 8.5-9.2 (3H, s, broad); 7.95-8.1 (1H, d); 7.85-8.0 (1H, s); 7.35-7.5 (1H, m); 7.15-7.35 (3H, m); 7.0-7.15 (1H, t); 6.85-7.0 (3H, m); 5.9-6.1 (1H, s, broad); 4.5-4.8 (2H, m, broad); 4.15-4.45 (3H, m, broad); 3.9-4.0 (3H, s); 3.75-4.0 (1H, m, broad); 2.8-3.05 (2H, m, broad); 2.55-2.75 (2H, m, broad).
    • Example 6 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(phenoxyethyl)-5,6,7,8-tetrahydro-imidazo[1.2a]pyrazine, dimer: 6
  • Compound 5.o (467 mg; 0.687 mmol) is solubilized in H2O (25 ml) and the pH of the solution is adjusted to 7.2 by adding a dilute aqueous solution of NH4OH. Acetonitrile is added in order to produce a limpid solution and the mixture is agitated at ambient temperature overnight. The crude product is purified by preparative HPLC on a C18 column using a gradient of 15 to 40% CH3CN in TFA at 0.1% over a period of 50 minutes. The pure fractions of product are collected and lyophilized. The initial product is lyophilized twice from a dilute solution of HCl in order to produce the product in the form of its hydrochloride (161 mg; 45%).
  • Mass spectrum: 903.5 MH+. NMR 1H (DMSO-d6 at 90° C.): 8.7-9.3 (3H, broad s); 7.95-8.1 (1H, d); 7.85-8.0 (1H, s); 7.3-7.5 (1H, t); 7.1-7.3 (3H, m); 7.0-7.15 (1H, t); 6.8-7.0 (3H, m); 5.85-6.1 (1H, broad s); 4.7-4.9 (1H, broad s); 4.45-4.7 (1H, broad m); 4.1-4.5 (4H, broad m); 3.85-4.0 (4H, s); 3.3-3.5 (2H, broad m); 2.5-2.8 (2H, broad m).
    • Example 7 7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(phenylsulphonylethyl)-5,6,7,8-tetrahydro-imidazo [1.2a]pyrazine: 7
  • Compound 7 was prepared according to the synthesis diagram below:
    Figure US20060035899A1-20060216-C00013
    • 7.p) 7-((1,1-dimethylethoxy)carbonyl)-2-(2-methoxyphenyl)-8-(phenylthioethyl)-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazine
  • Intermediate 5.1 (1.23 g; 3.30 mmol), tri-n-butylphosphine (1.64 ml; 6.60 mmol) and phenyldisulphide (1.44 g; 6.60 mmol) are mixed in THF (10 ml). The mixture is agitated at ambient temperature under argon for 4 hours. The solvents are eliminated under reduced pressure and the crude product is purified by flash chromatography on silica gel with an AcOEt:hexanes mixture 1:1 as eluant. The fractions containing the product are combined and concentrated under vacuum in order to produce the product in the form of a white foam (1.43 g; 93%).
  • Mass spectrum: 466.3 MH+.
    • 7.q) 7-((1,1-dimethylethoxy)carbonyl)-2-(2-methoxyphenyl)-8-(phenylsulphonylethyl)-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazine
  • Intermediate 7.p (650 mg; 1.40 mmol) is dissolved in CH2Cl2 (10 ml) and 3-chloroperoxybenzoic acid (483 mg; 2.80 mmol) is added in several portions over a period of 10 minutes. The mixture is poured onto a silica column and eluted with a hexanes:AcOEt mixture 7:3, then a hexanes:AcOEt mixture 1:1 in order to produce the pure product (220 mg; 32%).
  • Mass spectrum: 498.3 MH+. NMR 1H (DMSO-d6 at 30° C.): 7.9-8.0 (3H, m); 7.7-7.85 (1H, m); 7.6-7.75 (2H, m); 7.45-7.55 (1H,s); 7.15-7.25 (1H, m); 6.9-7.1 (2H, m); 5.1-5.25 (1H, t); 4.1-4.3 (1H, broad d); 4.0-4.15 (1H, m); 3.8-4.0 (1H, m); 3.85-3.95 (3H, s); 3.6-3.8 (1H, m); 3.4-3.6 (1H, m); 3.2-3.4 (H2O plus a blurred signal); 1.9-2.3 (2H,
    Figure US20060035899A1-20060216-P00999
    • Stage 7.n
  • Stage 7.n is carried out according to a method similar to Stage 5.n. The crude product is used without further purification in the following stage.
    • Stage 7.o
  • The stage 7.o is carried out according to a method similar to Stage 5.o.
  • Mass spectrum: 501.3 MH+.
    • Preparation of the Compound of Formula (VII)
  • This compound, which is close to those described in Patent Application PCT WO 97/30053, can be prepared according to the following synthesis diagram:
    Figure US20060035899A1-20060216-C00014
    • Pharmacological Part
  • In order to illustrate the usefulness of the invention, there follows a study on the effect of the treatment of a human MCF-7 cell line with the following compounds:
    • bis-1,1′-[7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine disulphide, designated in this part as compound (I);
    • bis-1,1′-7-(2-amino-1-oxo-3-thiopropyl-(2-(1-naphthyl)-8-(2-methylpropyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazin-7-yl), designated in this part as compound (II);
    • 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methylphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine, designated in this part as compound (III);
    • the compound of formula:
      Figure US20060035899A1-20060216-C00015
      designated in this part as compound (IV);
    • 7-(2-amino-1-oxo-3-thiopropyl)-8-butyl-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine, designated in this part as compound (V);
    • bis-1,1′-[7-(2-amino-1-oxo-3-thiopropyl)-2-(methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine], designated in this part as compound (VI);
    • the compound of formula:
      Figure US20060035899A1-20060216-C00016
      designated in this part as compound (VII);
      Procedures
  • Cell Line
  • The MCF-7 cell lines (human pleural cells, breast cancer) were acquired from the American Tissue Culture Collection (Rockville, Md., USA).
  • Measurement of the intracellular quantity of cyclic AMP for the MCF-7 cells
  • MCF-7 cells (2.104 cells/well) seeded in 24-well plates are cultured for 5 days in Dulbecco's modified Eagle medium (Gibco-Brl, Cergy-Pontoise, France) completed with 10% of foetal calf serum inactivated by heating (Gibco-Brl, Cergy-Pontoise, France), 50000 units/l of penicillin and 50 mg/l streptomycin (Gibco-Brl, Cergy-Pontoise, France), and 2 mM of glutamin (Gibco-Brl, Cergy-Pontoise, France). The culture medium is replaced after two washes with a medium without a serum completed or uncompleted with the specified agents for a time indicated in the different figures. Agents activating the production of cyclic AMP are then added at 37° C. The reaction is stopped after 30 minutes by suppressing the medium and rapidly adding 100 μl of a 0.1N solution of HCl. These extracts are frozen at −80° C. until they are used. The concentration of cAMP is measured using a commercial measurement kit (reference NEK033 from NEN, Les Ulis, France), following the manufacturer's instructions. The radioactivity is determined by a Gamma counter (Gamma Master-1277, LKB, Turku, Finland).
  • Measurement of in Vitro Cell Proliferation
  • The MCF-7 cells (3000 cells/well) are cultured in 96-well plates in 80 μl of Dulbecco's modified Eagle medium (Gibco-Brl, Cergy-Pontoise, France) completed with 10% of foetal calf serum inactivated by heating (Gibco-Brl, Cergy-Pontoise, France), 50000 units/l of penicillin and 50 mg/l streptomycin (Gibco-Brl, Cergy-Pontoise, France), and 2 mM of glutamin (Gibco-Brl, Cergy-Pontoise, France) were seeded on a 96-well plate on day 0. The cells were treated on day 1 for 96 hours with increasing concentrations of up to 50 μM of each of the compounds to be tested. After this period, quantification of cell proliferation is determined by a colorimetric test, based on the cleavage of the WST1 tetrazolum salt by the mitochondrial dehydrogenases in the viable cells, leading to the formation of formazan (Boehringer Mannheim, Meylan, France). These tests are carried out in duplicate with 8 determinations per concentration tested. For each compound to be tested, the values included in the linear part of the sigmoid were retained for linear regression analysis and used to estimate the inhibitory concentration (IC50).
  • Measurement of the MAP Kinase Activity
  • MCF7 cells (5.105 cells/well) are cultured in 6 wells in Dulbecco's modified Eagle medium (Gibco-Brl, Cergy-Pontoise, France) completed with 10% of foetal calf serum inactivated by heat (Gibco-Brl, Cergy-Pontoise, France), a mixture of antibiotics: 50000 units/l of penicillin and 50 mg/l of streptomycin (Gibco-Brl, Cergy-Pontoise, France) and 2 mM of glutamin (Gibco-Brl, Cergy-Pontoise, France). After 24 hours of culture, the cells are incubated for 48 hours in medium containing no serum in order to return the cells to a state of rest. The cells are then treated for 1 hour either with compound I or with PD98059 (Calbiochem, France Biochem, Meudon, France), a specific inhibitor of MAP kinase activation. The cells are then stimulated (or not) for 5 minutes with 12.5 ng/ml of epidermal growth factor (EGF). The reaction is stopped by two washes with PBS (Gibco-Brl, Cergy-Pontoise, France), at 4° C. containing neither calcium nor magnesium and by adding 150 μl of lysis buffer at 4° C. the composition of which is the following: 10 mM of tris, 150 mM of NaCl, 2 mM of EGTA, 2 mM of dithiothreitol, 1 mM of PMSF, 2 mM of orthovanadate, 10 μg/ml of leupeptin and 10 μg/ml of aprotinin. Measurement of the proteins contained in the extracts is carried out by Bradford's method (Biorad reagents, Ivry-Sur-Seine, France). These extracts are frozen at −80° C. until they are used. The activity of the MAP kinase is measured using a commercial measurement kit (reference RPN 84, Amersham Life Science, Les Ujis, France) following the manufacturer's instructions. The radioactivity is determined using a Packard scintillation counter (Tricarb 5000CA).
  • Equipment
  • The vasoactive intestinal peptide (VIP) was acquired from Bachem (Voisins le Bretonneux, France). The choleric toxin, forskolin, isoproterenol, prostaglandin E2 and PD 98059 were acquired from Calbiochem (France Biochem, Meudon, France). The compounds of formulae (I), (II), (III), (IV), (V), (VI) and (VII) were supplied by Biomeasure Inc. (Milford, Mass., USA). All these compounds were used following their manufacturers' recommendations.
  • Results
  • FIG. 1 shows that activation of the adenylate cyclase by the choleric toxin (200 ng/ml) or by forskolin (10 μM) leads to a very significant increase in the cyclic AMP level. Pretreatment of the cells for 30 minutes with 30 μM of comound (I) does not modify the production of cyclic AMP induced by the direct activator of the adenylate cyclase, forskolin. On the other hand, the production of cyclic AMP stimulated by the direct activator of the sub-unit, the choleric toxin, is greatly inhibited by compound (I). This shows that the adenylate cyclase itself is not modified by compound (I) and that the latter prevents the formation of the heterotrimeric complex.
  • VIP has been presented as an extra-cellular ligand of a receptor coupled with the G protein which stimulates the synthesis of cyclic AMP in human breast cancer cells. FIG. 2 shows that treatment with VIP of MCF-7 human breast cancer cells increases the intracellular quantity of cyclic AMP in a concentration-dependent manner. A VIP concentration of 10 nM which offers a quasi-optimum production of cyclic AMP is used for the following tests. This concentration agrees with the data already published relating to the T47D human breast cancer cell line.
  • FIG. 3 shows that a 30-minute pretreatment of the MCF-7 cells resulting from the in vitro cultures with the compound of formula (I) is sufficient to inhibit the accumulation of cyclic AMP cyclic stimulated by VIP in a concentration-dependent manner. An almost complete inhibition was obtained at a concentration of 100 μM of the compound of formula (I). These results show that a treatment with compound (I) is sufficient to block the transduction of the signal the route of which uses the heterotrimeric G proteins as mediators.
  • FIG. 4 shows that a treatment for an hour with the compound of formula (I) is sufficient to modify the response to VIP. Treatments of a longer duration (8 hours and 24 hours) continue to inhibit the production of cyclic AMP but the main effect is obtained very rapidly.
  • Compound (I) is also capable of inhibiting the formation of cyclic AMP induced by other agents which stimulate the receptors with seven transmembrane domains. In MCF7 cells, for example, the activity of the adenylate cyclase greatly increased by the prostaglandin E2 is inhibited by a treatment for 30 minutes with compound (I). This suggests that treatment of the cells with compound (I) modifies the heterotrimeric form of the G proteins by disassociating the sub-unit of the β/γ dimer.
  • Inhibition of stimulation by VIP is not restricted to compounds of a structure analogous to that of the compound of formula (I). As shown in Table I, compounds (II), (III), (IV), (V), (VI) and (VII) tested in the same model are also capable of reducing the quantity of cyclic AMP induced by VIP.
  • All these results suggest that the compounds tested modulate the activity of the adenylate cyclase by modifying the heterotrimeric form of the G proteins. Now, it is known that the β/γ dimers can directly activate effectors leading to the activation of kinases regulated by extracellular signals (ERK's) or MAP kinases.
  • FIG. 6 shows that treatment of the cells for 1 hour with compound (I) doubles the basal activity of the MAP kinase. This suggests that by preventing the formation of the heterotrimeric complex, compound (I) releases the heterodimer—which itself remains linked to the membrane and activates the ras route. On the other hand, FIG. 7 shows that after stimulation of the MAP kinase by the growth factor EGF for 5 minutes, the activity of the enzyme is increased by approximately 7 times. Pretreatment of the cells for 1 hour either with compound (I) or with PD98059, a specific inhibitor of MAP kinase activation, halves the activity of the MAP kinase. These results suggest that compound (I) stimulates the basal state of the ras route and inhibits this same route if it is stimulated, thus explainining its anti-proliferative effect.
  • Table II in fact shows that compounds (I), (II), (III) and (IV) are capable of inhibiting the in vitro proliferation of MCF7 human tumour cells.
    TABLE I
    Compound Inhibition at 30 μM
    (I) 86%
    (II) 71%
    (III) 59%
    (IV) 52%
    (V) 68%
    (VI) 52%
    (VII) 65%

    Effects of Compounds I, II, III and IV Incubated for 30 Minutes on the Production of Cyclic AMP Stimulated by VIP in MCF7 Cells.
  • The cells are incubated for 30 minutes in the presence or not of compounds I, II, III and IV (30 μM) which are then stimulated by 10−8 M of VIP. The quantification of cyclic AMP is determined by radioimmunoassay. The data represents the average ±MSD (n=5 for the control and n=1 for the different compounds ).
    TABLE II
    Compound tested IC50 (μM)
    compound I 9.4
    compound II 15.0
    compound III 16.1
    compound IV 34.6

    Inhibition of the in Vitro Growth of MCF7 Cells by Compounds I, II, III and IV.
  • The results of the IC50 are expressed in μM and represent the average of 2 experiments.

Claims (6)

1-12. (canceled)
13. A method of treating a disorder selected from oncogenesis, begnin and malign proliferative diseases in a patient comprising administering to said patient an amount of a compound of the formula
Figure US20060035899A1-20060216-C00017
wherein R1 is selected from the group consisting of hydrogen, lower alkyl and lower alkylthio, R2 and R3 are individually hydrogen or lower alkyl, R4 is
Figure US20060035899A1-20060216-C00018
or ═O, R5 is selected from the group consisting of a)hydrogen and b) lower alkyl, lower alkenyl, lower alkynyl, aryl, aryl lower alkyl, heterocycle and heterocycle lower alkyl, all unsubstituted or substituted with a member selected from the group consisting of lower alkyl, —O—R10, —S(O)m—R10,
Figure US20060035899A1-20060216-C00019
—NH—(SO2)—R11—COOR12
Figure US20060035899A1-20060216-C00020
m is an integer from 0 to 2, R6 and R7 are individually selected from the group consisting of a) hydrogen, b) unsubstituted
Figure US20060035899A1-20060216-C00021
and c) lower alkyl, aryl, aryl lower alkyl, heterocycle and heterocycle lower alkyl, unsubstituted or substituted with a member of the group consisting of —OH, halogen, lower alkyl, lower alkoxy,
Figure US20060035899A1-20060216-C00022
—COOH and
Figure US20060035899A1-20060216-C00023
or taken together with the carbon atom to which they are attached form aryl or heterocycle, R8 and R9 are individually selected from the group consisting of a) hydrogen and b) lower alkyl, aryl lower alkyl, heterocycle and heterocycle lower alkyl, all unsubstituted or substituted with a member of the group consisting of —OH, halogen, lower alkyl, lower alkoxy,
Figure US20060035899A1-20060216-C00024
taken together with the carbon atoms to which they are attached form aryl or heterocycle, R10 and R1 are individually selected from the group consisting of hydrogen, lower alkyl, aryl, aryl lower alkyl, heterocycle and heterocycle lower alkyl, R13 is unsubstituted lower alkyl or lower alkyl substituted with a member selected from the group consisting of aryl, aryl lower alkyl, heterocycle and heterocycle lower alkyl, R13 is unsubstituted lower alkyl or lower alkyl substituted with a member selected from the group consisting of lower alkyl, —O—R10, —S(O)m—R10 and
Figure US20060035899A1-20060216-C00025
R14 is hydrogen or lower alkyl, it being understood that Al can also be a dimmer when two R1 are hydrogen, and its non-toxic, pharmaceutically acceptable salts, sufficient to treat said disorder.
14. The method of claim 13 wherein the disorder is a begnin proliferative disease.
15. The method of claim 13 wherein the disorder is a malign proliferative disease.
16. The method of claim 13 wherein the compound used is selected from the group consisting of
7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methylphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
7-(2-amino-1-oxo-3-thiopropyl)-8-butyl-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1.2]pyrazine;
7-(2-amino-1-oxo-3-thiopropyl)-8-(1-methylpropyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
bis-1,1′-[7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine disulphide;
bis-1,1′-7-(2-amino-1-oxo-3-thiopropyl-(2-(1-naphthyl)-8-(2-methylpropyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazin-7-yl) disulphide;
7-(2-amino-1-oxo-3-thioprpyl)-8-(cyclohexylmethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(phenylmethoxy)methyl-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
7-(2-amino-2-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(1-phenylmethoxy)-ethyl-5,6,7,8-tetrahydroimidazo[1.2a-pyrazine;
7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(phenoxyethyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine;
7-(2-amino-1-oxo-3-thioproyl)-2-(2-methoxyphenyl)-8-(phenoxyethyl)-5,6,7,8-tetrahydro-imidazo[1.2a]pyrazine, or its dimeric form;
7-(2-amino-1-oxo-3-thiopropyl)-2-(2-methoxyphenyl)-8-(phenylsulphonylethyl)-5,6,7,8-tetrahydro-imidazo[1.2a]pyrazine;
and the non-toxic, pharmaceutically acceptable salts of the latter.
17. The method of claim 13 wherein the compound used is 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclhexylmethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine or a non-toxic, pharmaceutically acceptable salt of the latter.
US11/222,601 1998-07-08 2005-09-09 Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein Abandoned US20060035899A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/222,601 US20060035899A1 (en) 1998-07-08 2005-09-09 Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
FR9808731A FR2780974B1 (en) 1998-07-08 1998-07-08 USE OF IMIDAZOPYRAZINE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT FOR TREATING CONDITIONS RESULTING FROM THE FORMATION OF HETEROTRIMETER G PROTEIN
FR98/08731 1998-07-08
PCT/FR1999/001609 WO2000002881A2 (en) 1998-07-08 1999-07-05 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric g protein
US09/743,208 US6544995B1 (en) 1998-07-08 1999-07-05 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric G protein
US10/356,862 US7034025B2 (en) 1998-07-08 2003-02-03 Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein
US11/222,601 US20060035899A1 (en) 1998-07-08 2005-09-09 Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/356,862 Division US7034025B2 (en) 1998-07-08 2003-02-03 Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein

Publications (1)

Publication Number Publication Date
US20060035899A1 true US20060035899A1 (en) 2006-02-16

Family

ID=9528405

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/743,208 Expired - Fee Related US6544995B1 (en) 1998-07-08 1999-07-05 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric G protein
US10/356,862 Expired - Fee Related US7034025B2 (en) 1998-07-08 2003-02-03 Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein
US11/222,601 Abandoned US20060035899A1 (en) 1998-07-08 2005-09-09 Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/743,208 Expired - Fee Related US6544995B1 (en) 1998-07-08 1999-07-05 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric G protein
US10/356,862 Expired - Fee Related US7034025B2 (en) 1998-07-08 2003-02-03 Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein

Country Status (17)

Country Link
US (3) US6544995B1 (en)
EP (1) EP1100801B1 (en)
JP (1) JP2002520327A (en)
AR (1) AR019908A1 (en)
AT (1) ATE459625T1 (en)
AU (1) AU756268B2 (en)
CA (1) CA2336846C (en)
DE (1) DE69942095D1 (en)
ES (1) ES2341404T3 (en)
FR (1) FR2780974B1 (en)
MY (1) MY122419A (en)
NO (1) NO319633B1 (en)
NZ (1) NZ509789A (en)
RU (1) RU2268889C2 (en)
TW (1) TW561156B (en)
WO (1) WO2000002881A2 (en)
ZA (1) ZA200101061B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780974B1 (en) * 1998-07-08 2001-09-28 Sod Conseils Rech Applic USE OF IMIDAZOPYRAZINE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT FOR TREATING CONDITIONS RESULTING FROM THE FORMATION OF HETEROTRIMETER G PROTEIN
US7084135B1 (en) 1998-12-31 2006-08-01 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Prenyl transferase inhibitors
HUP0104708A3 (en) * 1998-12-31 2004-05-28 Sod Conseils Rech Applic Prenyl transferase inhibitors and medicaments containing them
DE10112926B4 (en) * 2001-03-13 2005-11-10 Schebo Biotech Ag Use of aminooxyacetate for tumor treatment
DE10112925A1 (en) * 2001-03-13 2002-10-02 Erich Eigenbrodt Use of sugar phosphates, sugar phosphate analogs, amino acids, amino acid analogs for modulating transaminases and / or the association p36 / malate dehydrogenase
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US20060052382A1 (en) * 2002-12-20 2006-03-09 Duffy Joseph L 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
FR2879460B1 (en) * 2004-12-17 2007-02-23 Sod Conseils Rech Applic ANTI-PAIN ASSOCIATIONS COMPRISING A DIHYDROIMIDAZOPYRAZINE DERIVATIVE
FR2921658A1 (en) * 2007-09-27 2009-04-03 Sod Conseils Rech Applic New pyrazolo-pyrazine derivatives are G protein inhibitors useful for preparing a medicament to treat or prevent disease or disorder e.g. cancer, non-tumor proliferative diseases, neurodegenerative diseases and parasitic diseases
CN101824036A (en) * 2009-03-05 2010-09-08 上海恒瑞医药有限公司 Salt of tetrahydroimidazo [1,5-a] pyrazine derivative, preparation method and pharmaceutical application thereof
AR077463A1 (en) 2009-07-09 2011-08-31 Irm Llc IMIDAZO DERIVATIVES [1, 2 - A] PIRAZINA AND ITS USE IN MEDICINES FOR THE TREATMENT OF PARASITARY DISEASES
MX2019012758A (en) 2017-04-24 2019-12-16 Novartis Ag Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorop henylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8h)- yl)ethanone and combinations thereof.
CN112480122B (en) * 2020-11-24 2022-03-22 中山大学 A kind of tetrahydroimidazo[1,2-a]pyrazine compound, composition and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544995B1 (en) * 1998-07-08 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric G protein
US6673927B2 (en) * 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
US7022704B2 (en) * 1996-02-16 2006-04-04 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2097378C1 (en) * 1991-03-26 1997-11-27 Ф.Хоффманн-Ля Рош Аг DERIVATIVES OF N-ACYL-α-AMINO ACID OR THEIR PHYSIOLOGICALLY ACCEPTABLE SALTS, SIMPLE ETHERS OR ESTERS, AMIDES OR HYDRATES AND COMPOSITION INHIBITING ADHESIVE PROTEINS BINDING WITH PLATELETS AND PLATELET AGGREGATION
DE69204007T2 (en) * 1991-10-11 1996-03-21 Squibb & Sons Inc Use of farnesyl-protein transferase inhibitors for the manufacture of a medicament for blocking neoplastic transformations of cells caused by Ras oncogenes.
GB9226065D0 (en) * 1992-12-14 1993-02-10 Ici Plc Peptides
US5705686A (en) * 1993-05-18 1998-01-06 University Of Pittsburgh Inhibition of farnesyl transferase
EP0703905A1 (en) * 1993-06-18 1996-04-03 Merck & Co. Inc. Inhibitors of farnesyl-protein transferase
AU702075B2 (en) * 1994-04-26 1999-02-11 Cadus Pharmaceutical Corporation Functional expression of mammalian adenylyl cyclase in yeast
CA2159850A1 (en) * 1994-11-03 1996-05-04 Yadagiri Pendri Phosphonosulfonate squalene synthetase inhibitor salts and method
AU4915796A (en) * 1995-01-12 1996-07-31 University Of Pittsburgh Inhibitors of prenyl transferases
FR2736638B1 (en) * 1995-07-12 1997-08-22 Rhone Poulenc Rorer Sa NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP0910385A4 (en) * 1996-04-15 1999-12-22 Univ Pennsylvania SENSITIZATION OF CELLS TO RADIATION THERAPY AND CHEMOTHERAPY
US5935812A (en) * 1996-09-18 1999-08-10 Incyte Pharmaceuticals, Inc. Human GTP binding protein gamma-3

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673927B2 (en) * 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
US7022704B2 (en) * 1996-02-16 2006-04-04 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
US6544995B1 (en) * 1998-07-08 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric G protein

Also Published As

Publication number Publication date
EP1100801B1 (en) 2010-03-03
CA2336846A1 (en) 2000-01-20
RU2268889C2 (en) 2006-01-27
NO20010029D0 (en) 2001-01-03
DE69942095D1 (en) 2010-04-15
EP1100801A2 (en) 2001-05-23
JP2002520327A (en) 2002-07-09
ES2341404T3 (en) 2010-06-18
WO2000002881A3 (en) 2000-03-16
NZ509789A (en) 2004-01-30
MY122419A (en) 2006-04-29
AU4622299A (en) 2000-02-01
FR2780974A1 (en) 2000-01-14
ATE459625T1 (en) 2010-03-15
WO2000002881A2 (en) 2000-01-20
NO319633B1 (en) 2005-09-05
US20030162786A1 (en) 2003-08-28
ZA200101061B (en) 2002-10-02
TW561156B (en) 2003-11-11
CA2336846C (en) 2010-03-16
AU756268B2 (en) 2003-01-09
US7034025B2 (en) 2006-04-25
FR2780974B1 (en) 2001-09-28
US6544995B1 (en) 2003-04-08
AR019908A1 (en) 2002-03-20
NO20010029L (en) 2001-01-08

Similar Documents

Publication Publication Date Title
US7034025B2 (en) Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein
HU228369B1 (en) Use of cgmp-phosphodiesterase inhibitors to treat impotence
AU688972B2 (en) Pyrimido{5,4-d}pyrimidines, drugs containing these compounds, their use, and process for preparing them
EP0699204A1 (en) Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US20060167080A1 (en) Wortmannin analogs and methods of using same
US6136798A (en) Compounds inhibiting the association of the PDGF receptor and phosphatidylinositol 3-kinase and their use
WO2002072101A1 (en) A corticotropin releasing factor receptor ligand, its enantiomer and pharmaceutically acceptable salts
US20220218715A1 (en) Novel use of pyrrolo-pyridine derivative compound for prevention and/or treatment of cancer
US8586626B2 (en) Metabolites of wortmannin analogs and methods of using the same
EP3475286B1 (en) Substituted pyrrolo [2, 3-d]pyridazin-4-ones and pyrazolo [3, 4-d]pyridazin-4-ones as protein kinase inhibitors
EP3955929B1 (en) New pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling
HU228067B1 (en) Memnopeptides, a process for their preparation and their use
JPH029819A (en) Antivasospasmodic agent and vasohypotonic agent
Shimazaki et al. Studies on inhibition of adenosine deaminase by isocoformycin in vitro and in vivo
EP1070067B1 (en) Cytotoxic alkaloid derivatives including asmarine a and b isolated from a sponge
KR20210135187A (en) ASK1 Inhibitor and Uses Thereof
Dimaline et al. A novel family of VIP-like peptides from the dogfish scyliorhinus canicula.
AIVAREZ et al. Inhibition of Parasite Protein Kinase C by
Álvarez Rueda et al. Inhibition of Parasite Protein Kinase C by New Antileishmanial Imidazolidin-2-one Compounds
Nelson et al. Cytotoxic effects of native epidermal growth factor (EGF) and a synthetic agonist on a human breast cancer cell line (MDA-MB-436).

Legal Events

Date Code Title Description
AS Assignment

Owner name: IPSEN PHARMA S.A.S., FRANCE

Free format text: CHANGE OF NAME;ASSIGNOR:SOCIETE DE CONSEILS DE RECHERCHES ET D`APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.);REEL/FRAME:022466/0793

Effective date: 20081128

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: IPSEN PHARMA S.A.S., FRANCE

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY NAME PREVIOUSLY RECORDED AT REEL: 022466 FRAME: 0793. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME;ASSIGNOR:SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S.;REEL/FRAME:038628/0931

Effective date: 20081128

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载